SLC22A2 and cancer: The organic cation transporter 2 (encoded by the SLC22A2 gene) is well characterized as uptake drug transporter for platinum drugs as well as other anti-cancer agents and the current FDA Guidance32 on “Drug Interaction Studies” recommends OCT2 as an important ADME target to be considered in the preclinical/clinical drug development process.